Related references
Note: Only part of the references are listed.Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey
Bruno C. Medeiros et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia
Kelly J. Norsworthy et al.
CLINICAL CANCER RESEARCH (2019)
Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis
Amer M. Zeidan et al.
CANCER (2019)
Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials
Jorge E. Cortes et al.
FUTURE ONCOLOGY (2019)
Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
Naveed Shaik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
Hedgehog Pathway Inhibitors and Their Utility in Basal Cell Carcinoma: A Comprehensive Review of Current Evidence
Evelyn Yu-Xin Tay et al.
DERMATOLOGY AND THERAPY (2019)
Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review
Anna Forsythe et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2019)
Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers
M. Naveed Shaik et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Geriatric Assessment in Older Patients with Acute Myeloid Leukemia
Kah Poh Loh et al.
CANCERS (2018)
Fatigue at baseline is associated with geriatric impairments and represents an adverse prognostic factor in older patients with a hematological malignancy
F. Hofer et al.
ANNALS OF HEMATOLOGY (2018)
Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events
Jorge E. Cortes et al.
BLOOD (2018)
Frailty and the management of hematologic malignancies
Gregory A. Abel et al.
BLOOD (2018)
Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells
Nobuaki Fukushima et al.
CANCER SCIENCE (2016)
Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerations
Jennifer E. Vaughn et al.
LEUKEMIA RESEARCH (2016)
Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
Mario E. Lacouture et al.
ONCOLOGIST (2016)
The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells
Giorgia Giordani et al.
ONCOTARGET (2016)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
Giovanni Martinelli et al.
LANCET HAEMATOLOGY (2015)
Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers
M. Naveed Shaik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
Alan K. Burnett et al.
BLOOD (2013)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Amanda F. Cashen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Hedgehog signaling maintains chemoresistance in myeloid leukemic cells
K. C. S. Queiroz et al.
ONCOGENE (2010)
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome
H Kantarjian et al.
CANCER (2006)
Share Paper
